Use of Activated Recombinant Human Factor VII in Cardiac Surgery
Public ClinicalTrials.gov record NCT00154427. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-centre, Randomised, Double-blind, Placebocontrolled, Dose Escalation Trial on Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Post-operative Bleeding in Patients Following Cardiac Surgery Requiring Cardiopulmonary Bypass
Study identification
- NCT ID
- NCT00154427
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 172 participants
Conditions and interventions
Interventions
- activated recombinant human factor VII Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2004
- Primary completion
- Oct 31, 2007
- Completion
- Oct 31, 2007
- Last update posted
- Jan 11, 2017
2004 – 2007
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Birmingham | Alabama | 35235 | — |
| Novo Nordisk Investigational Site | Tucson | Arizona | 85714 | — |
| Novo Nordisk Investigational Site | San Francisco | California | 94115 | — |
| Novo Nordisk Investigational Site | Denver | Colorado | 80262 | — |
| Novo Nordisk Investigational Site | Atlanta | Georgia | 30322 | — |
| Novo Nordisk Investigational Site | Baltimore | Maryland | 21287 | — |
| Novo Nordisk Investigational Site | Boston | Massachusetts | 02215 | — |
| Novo Nordisk Investigational Site | Camden | New Jersey | 08103 | — |
| Novo Nordisk Investigational Site | Syracuse | New York | 13210 | — |
| Novo Nordisk Investigational Site | The Bronx | New York | 10461 | — |
| Novo Nordisk Investigational Site | The Bronx | New York | 10467 | — |
| Novo Nordisk Investigational Site | Cleveland | Ohio | 44195 | — |
| Novo Nordisk Investigational Site | Oklahoma City | Oklahoma | 73117 | — |
| Novo Nordisk Investigational Site | Portland | Oregon | 97207 | — |
| Novo Nordisk Investigational Site | Danville | Pennsylvania | 17821 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77030 | — |
| Novo Nordisk Investigational Site | Norfolk | Virginia | 23507 | — |
| Novo Nordisk Investigational Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00154427, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 11, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00154427 live on ClinicalTrials.gov.